Claritev (NYSE:CTEV) Receives Average Rating of “Hold” from Analysts

Claritev (NYSE:CTEV) has received an average rating of “Hold” from the eight research firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $34.50.

A number of research firms have recently weighed in on CTEV. Weiss Ratings reissued a “sell (d-)” rating on shares of Claritev in a research report on Wednesday, June 24th. Zacks Research lowered shares of Claritev from a “hold” rating to a “strong sell” rating in a research report on Friday, July 17th. Citigroup reaffirmed a “buy” rating on shares of Claritev in a research note on Wednesday, May 13th. Wall Street Zen upgraded Claritev from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Canaccord Genuity Group increased their price target on Claritev from $32.00 to $37.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st.

Hedge Funds Weigh In On Claritev

Institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp boosted its stake in Claritev by 2.5% in the 1st quarter. Bank of New York Mellon Corp now owns 18,111 shares of the company’s stock worth $296,000 after buying an additional 447 shares during the last quarter. State of Wyoming acquired a new position in shares of Claritev during the 4th quarter valued at about $25,000. Ameritas Investment Partners Inc. acquired a new position in shares of Claritev during the 3rd quarter valued at about $42,000. Legal & General Group Plc purchased a new position in shares of Claritev during the 3rd quarter worth about $45,000. Finally, Invesco Ltd. lifted its holdings in shares of Claritev by 4.8% during the 4th quarter. Invesco Ltd. now owns 22,802 shares of the company’s stock worth $975,000 after acquiring an additional 1,044 shares during the period. 87.15% of the stock is currently owned by institutional investors and hedge funds.

Claritev Trading Up 19.2%

NYSE:CTEV opened at $32.00 on Friday. Claritev has a 12-month low of $11.50 and a 12-month high of $74.07. The firm has a market cap of $545.60 million, a price-to-earnings ratio of -1.88 and a beta of 0.74. The company’s 50-day moving average is $28.88 and its two-hundred day moving average is $23.79.

More Claritev News

Here are the key news stories impacting Claritev this week:

• Positive Sentiment: Better-than-expected quarterly performance: Claritev reported Q2 revenue of approximately $257.5 million, up 6.6% year over year. The company’s net loss narrowed to $59.2 million from $62.6 million, while adjusted EBITDA reached $155.8 million. Reported earnings also surpassed the consensus loss estimate, although published sources show differing EPS figures depending on the accounting presentation. Claritev Corporation Reports Second Quarter 2026 Results Claritev Reports Q2 Loss and Tops Revenue Estimates
• Positive Sentiment: Raised 2026 guidance: Management now expects full-year revenue of $1.0 billion to $1.02 billion and adjusted EBITDA of $610 million to $620 million. The revenue outlook is above the roughly $994.7 million analyst consensus, signaling confidence in continued operating momentum. Claritev Beats Second-Quarter Expectations and Raises Guidance
• Positive Sentiment: Improved cash generation: Operating cash flow increased to $92.7 million from $61.2 million a year earlier, while free cash flow rose to $54.6 million from $36.6 million. The gains provide additional support for the company’s financial flexibility. Claritev Q2 Revenue Rises 6.6 Percent
• Positive Sentiment: Favorable trading sentiment: Investor commentary focused on the earnings beat, higher guidance and increased trading volume. Six reported insider transactions over the past six months were purchases, with no reported sales, though insider activity is not a guarantee of future performance. Claritev Stock Opinions on Q2 Earnings Beat

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.